750 million! Two well-known pharmaceutical companies were sold.

Yesterday (June 15), Xinbang Pharmaceuticals announced that it will transfer 100% of its 100% stake in the wholly-owned subsidiary Of China Peptide Biochemical Co., Ltd. ("China Peptide Biochemicals") and 100% of the shares of Kangyong Bio Co., Ltd. ("Kangyong Bio") to Ted Pharmaceuticals (Zhejiang) Co., Ltd. for a price of 750 million.
it is understood that the peptide biochemical, Kangyong biological is mainly engaged in peptide API customized services and in vitro diagnostic reagents sales, business mainly concentrated in North America.
2019, sales revenue from polypeptides and in vitro diagnostic reagents accounted for 4.18% and 0.76% of the company's main business revenue, respectively.
affected by Sino-US trade friction, the new crown pneumonia outbreak and other adverse factors, the company's peptide business, in vitro diagnostic reagents business are facing development bottlenecks, Kangyong Bio 2019 and sino-peptide biochemical 2020 first quarter have a loss.
Xinbang Pharmaceuticals said that in order to seek a break to consider further increase in research and development investment and overseas investment in the construction of factories, large capital investment in the short term will inevitably adversely affect the overall operating performance of listed companies, financial situation.
, in order to avoid the above uncertainties that pose risks to the continued profitability of listed companies, optimize the company's asset structure, better allocate the company's resources, and implement a focus on medical services, the company intends to transfer the two companies to Ted Pharmaceuticals.
after the completion of this transaction, Sino-Peptide Biochemical sorority and Kangyong Bio are no longer subsidiaries of the company, no longer included in the scope of the company's consolidated statements, will focus on the company's main business, invigorate assets, enhance cash flow, reduce operating costs will have a positive impact. according to the public information of the
, Guizhou Xinbang Pharmaceutical Co., Ltd. is a whole-chain enterprise engaged in medical services, pharmaceutical circulation, pharmaceutical industry and other business. Founded in 1995,
has a registered capital of 1.667 billion yuan, total assets of 10.854 billion yuan, direct and indirect holding of more than 50 subordinate enterprises, the Group has nearly 7,000 employees.
company's pharmaceutical industry sector covers a variety of business, testing is the highlight of the sector.
in biomedicine, the four consecutive zero defects of peptide biochemistry through the United States FDA and the European Union on-site audit, products are exported to all continents.
has the world's leading peptide innovation technology, is the international 10 compulsory pharmaceutical enterprises and world-class scientific research institutions long-term stability of peptide partners.
sell so, why is Xinbang Pharmaceuticals eager to get rid of the peptide biochemistry? Notably, at the end of 2015, Sinbang Pharmaceuticals spent $2 billion to buy Peptide Biochemicals, in an effort to fill the gap in the company's biopharmaceutical sector.
according to the acquisition plan, the asset valuation value of Sino-Peptide Biochemicals reached 2 billion yuan, the capital increase rate reached 727.27%.
of the 2 billion yuan, Xinbang Pharmaceuticals paid 200 million yuan in cash.
peptide biochemical main business for customers customized peptides and drug peptides and in vitro diagnostic reagents three series, almost all of the company's business is abroad, which also buried its future reasons for being out of hand.
at that time, Sino-Peptide Biochemical forecast net profit for the next three years was 81.82 million yuan, 106 million yuan and 138 million yuan, respectively.
the acquisition, which ranges from $2bn to $700m, could be described as a "sell-off" - a rush to sell or related to the company's own performance.
since its listing in 2010, Xinbang Pharmaceuticals has achieved rapid performance growth, but the only exception occurred in 2018, when the company experienced a large loss, totalling 1.29 billion yuan;
data were the most intuitive: the growth rate of net profit after deducting from 2014 to 2019 was 256.68 percent, 22.71 percent, 17.82 percent, 60.45 percent, -535.92 percent and 117.79 percent, respectively.
new and changeable to adapt to the policy In fact, although Xinbang Pharmaceuticals is divided into medical services, pharmaceutical circulation and pharmaceutical industry three major sectors, but the proportion is not balanced: the 2019 annual report shows that the company has 57.73 percent of the revenue from pharmaceutical circulation, 29.2 percent of the income from medical services, 12.54 percent of income from pharmaceutical manufacturing.
, the pharmaceutical business covers the cultivation of Chinese medicine, Chinese medicine tablets and traditional Chinese medicine production and sales, peptide drugs and diagnostic reagents research and development, production and sales and many other fields, forming a closed industrial chain.
Chinese medicine, the company has 17 national base medicine catalog varieties, including the company's main varieties: Yixin Shu capsules, pulse blood well capsules, viheinn particles, ginkgo leaves, six-flavored anti-capsules, chastain coin capsules and so on.
has 24 national health insurance catalog varieties, of which joint sacs pills are exclusive varieties.
chinese medicine tablets, its production of raw herbs has achieved the origin base, the origin of medicinal herbs traceable, the source of varieties clear, to ensure the safety and stability of the quality of medicinal herbs and drink tablets, with the well-known Chinese hospitals to establish multi-level cooperative relations.
originally intended to sell it for a variety of reasons by acquiring a cake that targets biopharmaceuticals and in vitro reagents for biopharmaceuticals and in vitro reagents.
Although the pharmaceutical circulation accounted for the highest proportion of the company's revenue, but the gross margin of only 1.692 billion yuan.
As the growth of the pharmaceutical distribution industry slows and is greatly affected by medical reform, Xinbang Pharmaceuticals is also looking for new profit points.
has been the research institute that, in the context of medical reform policy, the search for new change is an important way for pharmaceutical companies to adapt, the company's high research and development investment for its technology moat to lay the foundation for the company's future to create new profit points.
perhaps, the determination to sell peptide biochemistry is the first step in the company's transformation.
.